Kopitović V, Bujas M, Fistes Topalski N, Pjević M, Ilić D, Kapamadzija A, Bujas I
Klinika za ginekologiju i akuserstvo, 21000 Novi Sad, Branimira Cosića 37.
Med Pregl. 2001 Jul-Aug;54(7-8):339-46.
This study investigated the efficacy of Zoladex depot 3.6 mg (goserelin acetate) during a 4-month treatment of infertile patients with uterine myomas of different size and location. The investigation comprised 30 patients aged 22-42 years, distributed into 2 groups regarding uterine and myoma volume. The first group included patients with uterine myomas less than 70 ml and uterus less than 300 ml. The second group included patients in whom these volumes exceeded the above mentioned values. Zoladex depot was administered every 28 days for 4 months with ultrasonographic follow-up of volume decrease, whereas patients with submucous myomas underwent control hysteroscopy. The obtained results point to efficacy of Zoladex in decreasing the volumes of both myomas and uterus by more than 50%, which correlates with literature data. Of particular interest is complete disappearance of myomas in about 60% of patients of the first group. Serum concentrations of follicle stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) were followed-up prior to and during Zoladex therapy where multivariate variance analysis showed statistically significant differences. The side effects were recorded and are similar to those of other GnRH analogues.
本研究调查了3.6毫克戈舍瑞林长效注射剂（醋酸戈舍瑞林）在为期4个月的治疗中，对不同大小和位置子宫肌瘤的不孕患者的疗效。该研究纳入了30名年龄在22至42岁之间的患者，根据子宫和肌瘤体积分为2组。第一组包括子宫肌瘤体积小于70毫升且子宫体积小于300毫升的患者。第二组包括这些体积超过上述值的患者。每28天给予戈舍瑞林长效注射剂，共4个月，并通过超声检查随访体积减小情况，而黏膜下肌瘤患者则接受对照宫腔镜检查。所得结果表明，戈舍瑞林可使肌瘤和子宫体积减小超过50%，这与文献数据相符。特别值得关注的是，第一组约60%的患者肌瘤完全消失。在戈舍瑞林治疗前和治疗期间对促卵泡激素（FSH）、促黄体生成素（LH）和雌二醇（E2）的血清浓度进行了随访，多变量方差分析显示存在统计学上的显著差异。记录了副作用，其与其他促性腺激素释放激素类似物的副作用相似。
